BPC-157 in the US: price and access

If you are in the US and trying to find out what BPC-157 costs, the pricing question cannot be separated from the regulatory one. BPC-157 has no FDA marketing approval^[1], no approved compounding pathway under section 503A or 503B, and no published price from any licensed US pharmacy. What exists is a grey market, with prices set by research-chemical vendors and no consumer-protection floor. This article explains why no official US price exists, what the grey-market landscape looks like, and what the July 2026 FDA advisory committee vote means for future access.

For the full compound profile, including mechanism, preclinical evidence, and cross-country regulation, see the BPC-157 peptide page.

Why there is no official US price for BPC-157

A published drug price requires a product that has gone through the FDA approval process: a new drug application, clinical trial data, and a marketing authorisation. BPC-157 has none of these. The FDA has no approved product for BPC-157 under any indication.^[1] There is no manufacturer's reference price, no Medicaid rebate calculation, and no CMS average sales price. The compound does not appear in any US drug pricing database because it is not a US drug.

Without approval, the two pathways that would give licensed pharmacies access to the compound are section 503A (traditional compounding pharmacies) and section 503B (outsourcing facilities). As of the date of this article, BPC-157 sits on neither the 503A permitted list nor the 503B analogous list. Any US pharmacy that compounds and sells BPC-157 is operating outside the clear boundaries of federal law.

The compounding history: Category 2, removal, and the July 2026 PCAC vote

The regulatory history of BPC-157 under the compounding framework is worth tracing carefully, because it is the source of considerable confusion in the market.

In 2023, the FDA placed BPC-157 on the Category 2 bulk drug substances list for section 503A compounding. Category 2 substances are those for which the FDA has identified significant safety concerns or insufficient information to support compounding use. Being on Category 2 is not a ban on possession, but it does mean a 503A pharmacy may not compound a finished product from BPC-157. The FDA's specific concern at that stage included immunogenicity risks and the absence of human clinical trial data.^[2]

In April 2026, the FDA removed BPC-157 from Category 2 following the withdrawal of the compound's nomination. This withdrawal did not move BPC-157 to the Category 1 permitted list. Removal from Category 2 created a transitional regulatory grey zone: BPC-157 was neither explicitly prohibited nor explicitly permitted for compounding.^[2]

On 23-24 July 2026, the FDA's Pharmacy Compounding Advisory Committee met and voted 8-6 (with one abstention) in favour of recommending that BPC-157 be added to the 503A bulk drug substances list.^[3] The vote is non-binding. The FDA's own scientific staff had reviewed the evidence and recommended against all seven peptides on the agenda, citing gaps in characterisation, effectiveness, and safety data. The committee's advisory role means the FDA must still decide whether to follow the recommendation, and a formal rulemaking process would follow any positive decision. As of this article's editorial date, BPC-157 remains outside the 503A permitted list.

The distinction matters for consumers. A PCAC vote is not the same as FDA approval, and it is not the same as compounding authorisation. A positive PCAC recommendation, if the FDA follows it, would allow licensed 503A pharmacies to compound BPC-157 for individual patients on a prescriber's order. It would not create an over-the-counter product, and it would not alter the absence of a marketing authorisation.

What 'research use only' labelling means in practice

The US Department of Defense's Operation Supplement Safety programme has described BPC-157 as both an unapproved drug and a substance prohibited for service members.^[4] Products sold online typically carry labels that read 'not for human consumption', 'research use only', or 'for in vitro research purposes only'. These labels are not neutral. They are the mechanism by which vendors attempt to place the product outside the FDA's jurisdiction over drugs intended for human use.

The strategy has limited legal effect. The FDA's definition of a drug covers any article intended to affect the structure or function of the body of humans. If a product is sold with marketing copy that implies human health benefits, the 'research use only' label does not prevent the FDA from treating it as an unapproved drug. OPSS frames this clearly: the labelling is a legal shield for the vendor, not a safety certification for the buyer.

A 2026 peer-reviewed review in Sports Medicine by Mendias and Awan confirmed that unapproved peptides including BPC-157 operate in a grey market with 'scant human safety data', and that their supply chain operates 'largely outside of regulatory oversight'.^[5] Independent purity testing of grey-market peptide vials has repeatedly found identity failures, contamination, and mislabelled concentrations. The 'research use only' designation provides no assurance on any of these points.

What BPC-157 costs in the US grey market

Because BPC-157 is not sold through licensed US pharmacies with a regulated pricing structure, any pricing discussion reflects observable grey-market patterns rather than official data. Research-chemical vendors in the US market BPC-157 in lyophilised powder form, most commonly in 5 mg vials. As of mid-2026, prices across the US research-chemical market run from approximately $22 to $60 per 5 mg vial, with per-milligram pricing across vendors in roughly the $3 to $8 range. Multi-vial bundles typically come at proportional discounts.

These numbers are drawn from publicly observable vendor listings and price-comparison aggregators, not from licensed pharmaceutical databases. They shift without notice and reflect neither quality assurance nor legal market dynamics. A lower price does not mean a better product; it may mean less rigorous third-party testing, a different purity level, or a vendor operating with less regulatory visibility.

If BPC-157 were added to the 503A permitted list and licensed compounding pharmacies began producing it, the pricing structure would change substantially. Compounded prescriptions are priced by the pharmacy and not reimbursed by standard US insurance plans for unapproved compounds. Market reports from early 2026 placed compounded BPC-157 pricing at approximately $150 per month or more when it was being prepared by some pharmacies operating in the grey zone. This figure carries no verification from a licensed pricing database and should be treated as an illustrative range only.

These price ranges are informational only. PeptideMethods does not recommend grey-market sourcing, and nothing in this article should be read as endorsing any vendor or supply channel.

Insurance coverage, Medicare, and Medicaid

Because BPC-157 is not an FDA-approved drug, it is not eligible for coverage under Medicare Part D or any standard US private insurance formulary. Medicaid programmes do not cover unapproved drugs. Even if the 503A compounding pathway opens following the PCAC vote, compounded preparations are generally excluded from insurance coverage in the US. Any cost would be entirely out of pocket.

There is no billing code, no national drug code entry, and no reimbursement pathway of any kind for BPC-157 in the current US system. For comparison, FDA-approved peptide drugs with established pricing structures (such as semaglutide under Ozempic or Wegovy, or tesamorelin under Egrifta) carry list prices published by manufacturers and have at least partial reimbursement pathways for qualifying patients. BPC-157 has none of these supports.

WADA prohibition for US athletes

For competitive athletes, the cost-access question is secondary to the prohibition question. BPC-157 sits on the World Anti-Doping Agency Prohibited List under S0 (non-approved substances), meaning it is banned both in-competition and out-of-competition for all athletes subject to the WADA Code.^[4] The US Anti-Doping Agency has published explicit guidance confirming this, and a US speed skater received a one-year ban in 2024 after a product containing BPC-157 was detected.

There is no therapeutic use exemption pathway for BPC-157 because it holds no approved indication anywhere. A PCAC recommendation to permit compounding would not alter WADA's prohibition. Athletes should treat the S0 listing as the settled starting point before considering any pricing or access question.

What is not covered here

This article covers BPC-157's pricing and regulatory landscape in the US. It does not cover the compound's mechanism of action, the preclinical rodent literature on tendon, gut and brain repair, or the clinical evidence picture. Those are covered on the BPC-157 peptide page. The cross-country regulatory comparison is at /regulation/united-states.

This article does not represent legal or medical advice. The regulatory picture described reflects the position as of 27 July 2026 and is subject to change. The FDA has not yet acted on the July 2026 PCAC recommendation. Consult a qualified prescriber and, if relevant, a qualified legal adviser before acting on any information here.

What we do not yet know

The biggest open question underlying the pricing landscape is whether BPC-157 works in humans at any dose, for any indication. No completed phase-2 or phase-3 randomised controlled trial of BPC-157 for any systemic indication has been published. The rodent literature is extensive, but rodent safety and efficacy data do not automatically translate to humans, and no dose-finding work in humans establishes a therapeutic window.^[5]

The July 2026 PCAC vote leaves the most consequential question open: whether the FDA will follow the committee's recommendation, and if so, on what timeline and with what conditions. A positive FDA decision on 503A compounding would shift the pricing structure for US consumers, but it would not make BPC-157 an approved drug, and it would not resolve the safety questions the FDA's own scientists raised before the vote.

We will update this page when the FDA acts on the PCAC recommendation. For the latest on the broader US regulatory picture for peptides, see the US regulation hub. If you are considering BPC-157 for a specific health goal, that conversation belongs with a clinician who can assess your situation against the absence of human trial data.